Isosteviol reduces plasma glucose levels in the intravenous glucose tolerance test in Zucker diabetic fatty rats

被引:53
作者
Ma, J.
Ma, Z.
Wang, J. [1 ]
Milne, R. W.
Xu, D.
Davey, A. K.
Evans, A. M.
机构
[1] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Adelaide, SA 5000, Australia
[2] Shanxi Med Univ, Affiliated Hosp 2, Taiyuan, Peoples R China
关键词
insulin; intravenous glucose tolerance test; isosteviol; stevioside; Zucker diabetic fatty rats;
D O I
10.1111/j.1463-1326.2006.00630.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The aim of this study was to test the effect of isosteviol on blood glucose and insulin levels during the intravenous glucose tolerance test (IVGTT) in Wistar and Zucker diabetic fatty (ZDF) rats. Methods: ZDF rats were divided into a control and three isosteviol treatment (1, 5 and 10 mg/kg) groups. Wistar rats were divided into a control group and an isosteviol treatment group (10 mg/kg). The rats were fasted for 12 h prior to infusion of isosteviol and glucose (1.0 g/kg). Blood samples were taken at 0, 5, 15, 30, 60, 90 and 120 min after the injection of glucose. Glucose concentrations were determined by the glucose oxidase method, and plasma insulin was analysed by radioimmunoassay. The area under the curve (AUC) of the net change in plasma glucose concentration was used to compare the isosteviol treatment and control groups. Results: In ZDF rats, isosteviol at 5 and 10 mg/kg caused a significant (p < 0.05) reduction in the AUC of glucose during the IVGTT. However, isosteviol did not increase plasma insulin concentrations in ZDF rats. In Wistar rats, isosteviol did not significantly affect plasma glucose or insulin levels during the IVGTT. Conclusion: Isosteviol exerts an antihyperglycaemic effect during IVGTT in ZDF rats but not in Wistar rats. Isosteviol has no significant effect on plasma insulin concentrations. The glucose-lowering effect of isosteviol may be due to changes in the sensitivity of peripheral tissues to insulin.
引用
收藏
页码:597 / 599
页数:3
相关论文
共 8 条
[1]   Antihyperglycemic effects of stevioside in type 2 diabetic subjects [J].
Gregersen, S ;
Jeppesen, PB ;
Holst, JJ ;
Hermansen, K .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (01) :73-76
[2]  
HERMANSEN K, 2001, Patent No. 2001056959
[3]   Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: A two-year, randomized, placebo-controlled study [J].
Hsieh, MH ;
Chan, P ;
Sue, YM ;
Liu, JC ;
Liang, TH ;
Huang, TY ;
Tomlinson, B ;
Sum, MS ;
Kao, PF ;
Chen, YJ .
CLINICAL THERAPEUTICS, 2003, 25 (11) :2797-2808
[4]   Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo:: studies in the diabetic Goto-Kakizaki (GK) rats [J].
Jeppesen, PB ;
Gregersen, S ;
Alstrup, KK ;
Hermansen, K .
PHYTOMEDICINE, 2002, 9 (01) :9-14
[5]   Effects of stevioside on glucose transport activity in insulin-sensitive and insulin-resistant rat skeletal muscle [J].
Lailerd, N ;
Saengsirisuwan, V ;
Sloniger, JA ;
Toskulkao, C ;
Henriksen, EJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (01) :101-107
[6]   METABOLICALLY ACTIVATED STEVIOL, THE AGLYCONE OF STEVIOSIDE, IS MUTAGENIC [J].
PEZZUTO, JM ;
COMPADRE, CM ;
SWANSON, SM ;
NANAYAKKARA, NPD ;
KINGHORN, AD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (08) :2478-2482
[7]   Developmental toxicity of steviol, a metabolite of stevioside, in the hamster [J].
Wasuntarawat, C ;
Temcharoen, P ;
Toskulkao, C ;
Mungkornkarn, P ;
Suttajit, M ;
Glinsukon, T .
DRUG AND CHEMICAL TOXICOLOGY, 1998, 21 (02) :207-222
[8]   INTESTINAL DEGRADATION AND ABSORPTION OF THE GLYCOSIDIC SWEETENERS STEVIOSIDE AND REBAUDIOSIDE-A [J].
WINGARD, RE ;
BROWN, JP ;
ENDERLIN, FE ;
DALE, JA ;
HALE, RL ;
SEITZ, CT .
EXPERIENTIA, 1980, 36 (05) :519-520